FLT3 and acute myeloid leukemia: Quizartinib has been approved in Japan for the treatment of patients with relapsed or refractory FLT3-mutated AML (Takahashi et al., 2019; Usuki et al., 2019), and it has shown good efficacy in clinical trials even at low doses (Fletcher et al., 2020).